Direxion Daily S&P Biotech Bear 3X ETF
LABD
16 hedge funds and large institutions have $44.7M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.
307% more call options, than puts
Call options by funds: $19.6M | Put options by funds: $4.82M
8% more capital invested
Capital invested by funds: $41.2M → $44.7M (+$3.45M)
5.32% less ownership
Funds ownership: 21.85% → 16.53% (-5.3%)
16% less funds holding
Funds holding: 19 → 16 (-3)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.8M |
| 2 |
VF
Virtu Financial
New York
|
+$1.76M |
| 3 |
Jane Street
New York
|
+$1.17M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$347K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$7.79M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.15M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.44M |
| 4 |
CA
CHI Advisors
New York
|
-$1.62M |
| 5 |
Squarepoint
New York
|
-$680K |
LABD Hedge Fund Activity: Q3 2023 in Review
16 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q3 2023, worth a combined $44.7M — up 8.4% from $41.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LABD and 1 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Goldman Sachs, adding an estimated $3.8M. The largest seller was HRT Financial, cutting an estimated $7.79M.
- 16 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q3 2023, down from 19 in Q2 2023.
- Funds reported $44.7M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q3 2023, up 8.4% quarter-over-quarter.
- 1 fund opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q3 2023 and 4 closed out, a net change of -3 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q3 2023 was Goldman Sachs, an estimated $3.8M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q3 2023 was HRT Financial, an estimated $7.79M sold.
Based on aggregated 13F filings for Q3 2023.